Abstract: A die or piston of a spark plasma sintering apparatus, wherein the die or piston is made from graphite and the outer surfaces of the die or piston are coated with a silicon carbide layer with a thickness of 1 to 10 micrometres, the silicon carbide layer being further optionally coated with one or more other layer(s) made from a carbide other than silicon carbide chosen from hafnium carbide, tantalum carbide and titanium carbide, the other layer(s) each having a thickness of 1 to 10 micrometres. A spark plasma sintering (SPS) apparatus comprising the die and two of the pistons, defining a sintering, densification or assembly chamber capable of receiving a powder to be sintered, a part to be densified, or parts to be assembled. A method of sintering a powder, densifying a part, or assembling two parts by means of a method of spark plasma sintering (SPS) in an oxidising atmosphere, using the spark plasma sintering (SPS) apparatus.

Abstract: The invention relates to a monoethylenically unsaturated monomer of formula (I), and to the use thereof for producing a polymer. The invention also relates to the polymer obtained by polymerising said monomer, and to the use thereof in a composition for producing coatings.

Abstract: The present invention provides protected tetrasaccharides, their process of preparation and their use in the synthesis of oligosaccharides, in particular fragments of O-antigens from Shigella flexneri, for example of serotype 1a, 1b, 2a, 2b, 3a, X, 4a, 4b, 5a, 5b, 7a or 7b.

Abstract: A process for producing a protein isolate from an oilseed meal, and the isolate thus obtained, said isolate comprising proteins and an amount of 4 wt. % or less of phytic acid, said amount of phytic acid being by weight of proteins in said isolate. The process may comprise the following steps: a) providing an oilseed meal; b) mixing the oilseed meal with a first aqueous solvent to form a slurry at a pH ranging from 6 to 7.8, said slurry having a solid phase; c) separating said solid phase from said slurry, d) mixing said separated solid phase with a second aqueous solvent at a pH ranging from 1 to 3.

Abstract: A method of predicting the risk of recurrence in a subject undergoing treatment for, or having undergone treatment for, clear cell renal cell carcinoma (ccRCC), by comparing the level of extracellular vesicles, preferably microvesicles, expressing carbonic anhydrase 9 (CA9+ MVs) in a sample from the subject with a reference level. Also, a method of diagnosing ccRCC or identifying a risk of developing ccRCC, by comparing the level of CA9+ MVs in a sample from the subject with a reference level.

Abstract: The present invention concerns a compound of formula (I): or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity, in particular ERK2 activity.

Abstract: A spectroscopy device including: an electron source arranged to emit a flux of electrons towards a sample, a pulsed photon source emitting photon pulses towards the sample, at least one spectrometer for receiving a flux of electrons originating from the sample, at least one electron detector; and at least one deflector, between the electron source and the at least one electron detector, synchronized with the pulsed photon source to allow or prevent the passage of electrons emitted by the electron source, towards the electron detector.

Abstract: The present invention concerns a polymer comprising repetitive units having the following formula (I) wherein R1 is H or Me; L is a linker; R2 is the side chain of an ?-amino acid being other than arginine; m is 0 or an integer comprised from 1 to 10; n is an integer comprised from 1 to 10; and X— is a counterion.

Abstract: The invention relates to a process for selecting aptamers substrates of one helicase enzyme, comprising the implementation of a helicase SELEX process comprising several cycles, wherein each cycle comprises the following steps: a) Providing a library of nucleic acid duplex constructs comprising one nucleic acid strand containing a random sequence of 10 to 100 nucleotides framed by fixed sequences at each end; b) Incubation of said library with said helicase in appropriate conditions for the dissociation of certain duplex constructs by the helicase, resulting in release of the aptamers substrates of the helicase; c) Isolation and amplification of said aptamers substrates of the helicase; d) Creation of a novel library of nucleic acid duplex constructs enriched in duplex constructs comprising aptamers substrates of the helicase.

Abstract: The present invention relates to a compound of the following general formula (I): or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.

Abstract: A process for manufacturing chromenes intended for the preparation of thermosetting resins, includes transforming an aromatic propargyl ether of general formula (I) into a chromene by homogeneous gold(I) catalysis with the catalyst (acetonitrile)[(2-biphenyl)di-tert-butylphosphine]gold(I) hexafluoroantimonate in an organic solvent under an inert or non-inert atmosphere. Moreover, a process for preparing a material made of thermoset resin, includes successively a) implementation of the above process; polymerization of the reaction product obtained in step a) so as to obtain the material made of thermoset resin; c) recovery of the material made of thermoset resin obtained in step b).

Abstract: The present invention relates to an expression system for systemic administration comprising a sequence encoding a protein, said expression system allowing: the expression at a therapeutically acceptable level of the protein in the target tissues including skeletal muscles; and the expression at toxically acceptable level of the protein in tissues other than the target tissues, especially in the heart.

Abstract: A nickel-based superalloy includes, in atomic percentages, 13% to 21% chromium, 15% to 26% cobalt, 4% to 8% aluminum, 4.5% to 8% titanium, 8% to 18% iron, boron in an atomic percentage less than or equal to 0.5% or no boron, carbon in an atomic percentage less than or equal to 1% or no carbon, at least one additional element selected from molybdenum, tungsten, tantalum and niobium, a total atomic content of the at least one additional element being less than or equal to 1.5% or no such at least one additional element, the remainder being nickel and unavoidable impurities, with a sum of the atomic percentages of aluminum and titanium being comprised between 8.5% and 15%. The novel superalloy composition has a limited density and exhibiting, when hot, good mechanical properties as well as good resistance to oxidation and corrosion.

Abstract: A process for preparing in situ an aqueous gel ink with fixed color comprising the following steps: (i) preparing a gel-based matrix of aqueous ink comprising ester(s) of retinol represented by formula (I), and (ii) adding a solution of gold salts (Au3+) to the gel-based matrix of aqueous ink prepared in step (i), to obtain an aqueous gel ink with fixed color with gold nanoparticles dispersed therein. An aqueous gel ink with fixed color obtained according to the process of the invention, comprising the ester of retinol represented by formula (I) and gold nanoparticles. A writing instrument comprising an aqueous gel ink with fixed color.

Abstract: A bioelectrochemical reactor (1) has an anode chamber (11) having at least two bioanodes (12, 13), and an anodic electrolyte (14) with an anodic electroactive microorganisms,—a cathode chamber (21) with at least one biocathode (22), and a cathodic electrolyte (24) with a cathodic electroactive microorganisms. The anode chamber (11) is separated from the cathode chamber (21) by, running from the anode chamber to the cathode chamber, a cation exchange membrane (31) and an anion exchange membrane (32). The cation and anion exchange membranes are separated from each other by an inter-membrane chamber (30), and means for applying a potential difference between the interconnected bioanodes and the biocathode/biocathodes. The bioanodes and biocathode/biocathodes have active surfaces such that the total active surface of the biocathode/biocathodes (22) is greater than the total active surface of the two bioanodes (12, 13).

Abstract: An elementary particle detector including first sensors able to measure an amount of electric charge on electrodes of a readout plate and a processing unit able to determine the location of an avalanche of secondary electrons from the amount of electric charge measured by the first sensors and from the known location of the electrodes. The detector also includes at least one second sensor, each second sensor being able to measure an electrical signal produced by the secondary electrons when they pass through a conductive gate. The processing unit is additionally able to establish an arrival time of the elementary particle from a time at which the electrical signal is measured by the second sensor.

Abstract: Three-dimensional body implants including a hydrogel, which includes cross-linked alginate and gelatin, and in particular breast implants. The hydrogel of the implants has a mechanical strength of 1 kPa to 1000 kPa, and the hydrogel of the implants may further include fibrinogen. The implants include a porous zone, and the implants are acellular, i.e., free of cells during their manufacture.

Abstract: An active implantable medical device including, once implanted, a module external to the patient and a module inside the patient, the external module and the internal module being intended to transfer energy and data from one to the other. Also, a method for transferring energy and data, the method being implemented by the active implantable medical device.

Abstract: A monitoring device of biological cells including: a fluidic channel in which a fluid including biological cells is made to flow, including a first and second glass walls placed in parallel and a reflective surface adjoined to the second wall; and a piezoelectric transducer, the piezoelectric transducer emitting acoustic waves creating a force acting on the biological cells, making them flow substantially along a single motion plane. The external interface between the first wall and the exterior of the fluidic channel and the reflective surface are configured to function as a Fabry-Perot interferometer, such that the motion planes sensibly perpendicular to the optical axis of the Fabry-Perot interferometer. The finesse of the interferometer is lower than 10.

Abstract: A memory cell, includes first and second main terminals, an auxiliary terminal; M memristor(s) between the main terminals, M?1; M primary switch(es), each in parallel with a memristor; and a secondary switch between the second main terminal and the auxiliary terminal. It is configured for writing to at least one memristor by opening each primary switch in parallel with the at least one memristor, closing each other primary switch, closing the secondary switch and applying a corresponding programming voltage between the first main terminal and the auxiliary terminal; and for reading at least one memristor by opening each primary switch in parallel with the at least one memristor, closing each other possible primary switch, opening the secondary switch and measuring a corresponding electrical quantity between the main terminals.